BibTex format
@article{Pinato:2022:10.1016/S1470-2045(22)00273-X,
author = {Pinato, DJ and Aguilar-Company, J and Ferrante, D and Hanbury, G and Bower, M and Salazar, R and Mirallas, O and Sureda, A and Plaja, A and Cucurull, M and Mesia, R and Townsend, S and Jackson, A and Dalla, Pria A and Newsom-Davis, T and Handford, J and Sita-Lumsden, A and Apthorp, E and Vincenzi, B and Bertuzzi, A and Brunet, J and Lambertini, M and Maluquer, C and Pedrazzoli, P and Biello, F and Sinclair, A and Bawany, S and Khalique, S and Rossi, S and Rogers, L and Murphy, C and Belessiotis, K and Carmona-Garcia, MC and Sharkey, R and Garcia-Illescas, D and Rizzo, G and Perachino, M and Saoudi-Gonzalez, N and Doonga, K and Fox, L and Roldan, E and Gaidano, G and Ruiz-Camps, I and Bruna, R and Patriarca, A and Martinez-Vila, C and Cantini, L and Zambelli, A and Giusti, R and Mazzoni, F and Caliman, E and Santoro, A and Grosso, F and Parisi, A and Queirolo, P and Aujayeb, A and Rimassa, L and Prat, A and Tucci, M and Libertini, M and Grisanti, S and Mukherjee, U and Diamantis, N and },
doi = {10.1016/S1470-2045(22)00273-X},
journal = {The Lancet Oncology},
pages = {865--875},
title = {Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study},
url = {http://dx.doi.org/10.1016/S1470-2045(22)00273-X},
volume = {23},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BackgroundThe omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe.MethodsIn this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing.FindingsAs of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47·4%] were women and
AU - Pinato,DJ
AU - Aguilar-Company,J
AU - Ferrante,D
AU - Hanbury,G
AU - Bower,M
AU - Salazar,R
AU - Mirallas,O
AU - Sureda,A
AU - Plaja,A
AU - Cucurull,M
AU - Mesia,R
AU - Townsend,S
AU - Jackson,A
AU - Dalla,Pria A
AU - Newsom-Davis,T
AU - Handford,J
AU - Sita-Lumsden,A
AU - Apthorp,E
AU - Vincenzi,B
AU - Bertuzzi,A
AU - Brunet,J
AU - Lambertini,M
AU - Maluquer,C
AU - Pedrazzoli,P
AU - Biello,F
AU - Sinclair,A
AU - Bawany,S
AU - Khalique,S
AU - Rossi,S
AU - Rogers,L
AU - Murphy,C
AU - Belessiotis,K
AU - Carmona-Garcia,MC
AU - Sharkey,R
AU - Garcia-Illescas,D
AU - Rizzo,G
AU - Perachino,M
AU - Saoudi-Gonzalez,N
AU - Doonga,K
AU - Fox,L
AU - Roldan,E
AU - Gaidano,G
AU - Ruiz-Camps,I
AU - Bruna,R
AU - Patriarca,A
AU - Martinez-Vila,C
AU - Cantini,L
AU - Zambelli,A
AU - Giusti,R
AU - Mazzoni,F
AU - Caliman,E
AU - Santoro,A
AU - Grosso,F
AU - Parisi,A
AU - Queirolo,P
AU - Aujayeb,A
AU - Rimassa,L
AU - Prat,A
AU - Tucci,M
AU - Libertini,M
AU - Grisanti,S
AU - Mukherjee,U
AU - Diamantis,N
AU - Fusco,V
AU - Generali,D
AU - Provenzano,S
AU - Gennari,A
AU - Tabernero,J
AU - Cortellini,A
DO - 10.1016/S1470-2045(22)00273-X
EP - 875
PY - 2022///
SN - 1213-9432
SP - 865
TI - Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
T2 - The Lancet Oncology
UR - http://dx.doi.org/10.1016/S1470-2045(22)00273-X
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000833519600029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR - https://www.sciencedirect.com/science/article/pii/S147020452200273X?via%3Dihub
VL - 23
ER -